ClinicalTrials.gg
CompletedNCT04373902PinCUpdated Sep 25, 2026

Physiological-based Cord Clamping in Congenital Diaphragmatic Hernia

An interventional study of Physiological-based cord clamping in Hernias, Diaphragmatic, Congenital, Hernia; Diaphragm Defect, Congenital and Pulmonary Hypertension, sponsored by Erasmus Medical Center. Completed at 9 sites in 7 countries. Open to participants aged 35 Weeks and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Erasmus Medical Center · Not applicable, Interventional, and Prevention

How we know · 2 judgments

Updated Sep 25, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
35 Weeks and older
Sex
All
01

Study summary

Pulmonary hypertension is a major determinant of postnatal survival in infants with a congenital diaphragmatic hernia (CDH). The current care during the perinatal stabilisation period in infants born with this rare birth defect might contribute to the development of pulmonary hypertension after birth - in particular umbilical cord clamping before lung aeration. An ovine model of diaphragmatic hernia demonstrated that cord clamping after lung aeration, called physiological-based cord clamping (PBCC), avoided the initial high pressures in the lung vasculature while maintaining adequate blood flow, thereby avoiding vascular remodelling and aggravation of pulmonary hypertension. The investigators aim to investigate if the implementation of PBCC in the perinatal stabilisation period of infants born with a CDH could reduce the incidence of pulmonary hypertension in the first 24 hours after birth.

The investigators will perform a multicentre, randomised controlled trial in infants with an isolated CDH. Before birth, infants will be randomised to either PBCC or immediate cord clamping, stratified by treatment centre and severity of pulmonary hypoplasia on antenatal ultrasound. For performing PBCC a purpose-designed resuscitation module (the Concord Birth Trolley) will be used.

02

Conditions studied

  • Hernias, Diaphragmatic, Congenital
  • Hernia; Diaphragm Defect, Congenital
  • Pulmonary Hypertension

Keywords

  • Congenital diaphragmatic hernia
  • Perinatal stabilisation
  • Resuscitation
  • Pulmonary hypertension
  • Birth defect
  • Physiological-based cord clamping
03

In context

Hernias, Diaphragmatic, Congenital

86 studies on the registry are indexed under Hernias, Diaphragmatic, Congenital; 39 are open to participants now.

This study's enrollment of 144 is above the median of 30 across 62 interventional studies indexed under Hernias, Diaphragmatic, Congenital.

Browse Hernias, Diaphragmatic, Congenital studies →

Lead sponsor

Erasmus Medical Center is the lead sponsor of 479 studies on the registry; 182 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Weeks and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Left-sided CDH
  • Isolated CDH: no associated structural or genetic abnormalities that are diagnosed before birth
  • Gestational age at delivery ≥35.0 weeks
  • Parental written

Exclusion criteria

Exclusion Criteria:

  • Right-sided or bilateral CDH
  • Gestational age at delivery \<35.0 weeks
  • Maternal : anterior placenta praevia, placental abruption
  • High urgency caesarean section, with intended interval to delivery \<15 min
  • Cases that have been treated during pregnancy with experimental drug therapy aiming to decrease the occurrence of pulmonary hypertension
  • Twin pregnancies in which the infant diagnosed with a CDH is born first
  • Multiple birth >2 (triplets or higher order)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
144 participants (actual)

Study arms

  • Experimental
    Physiological-based cord clamping

    In PBCC, the Concord will be placed next to the bed of the mother and all equipment will be checked before the second stage of labour has started. The infant will be placed on the platform of the Concord immediately after birth, avoiding any traction or pressure on the cord and avoiding heat loss by radiation heating. The umbilical cord will not be clamped until the infant is considered respiratory stable, which is defined as the presence of a heart rate \>100 bpm and preductal oxygen saturation \>85%, while using an fraction of inspired oxygen (FiO2) of \<0.5. The minimum and maximum times of cord clamping are three and ten minutes after birth, respectively. Oxytocin administration will be postponed until after cord clamping if there are no obstetric concerns. At any time, the attending neonatologist and obstetrician can decide that PBCC should not be performed or be interrupted. In that case, the infant can be placed on the standard resuscitation table for (further) stabilisation.

    Procedure: Physiological-based cord clamping

  • No intervention
    Immediate cord clamping

    In the immediate cord clamping group, the cord will be clamped immediately after birth. The infant will then be transferred to the standard neonatal resuscitation table. After cord clamping, all infants will be managed according to the standardised neonatal management protocol for infants with a CDH, which is a consensus of current clinical guidelines by the CDH EURO consortium.

Interventions

  • ProcedurePhysiological-based cord clamping

    See 'Arm'

06

What researchers measure

Primary outcomes

  1. Number of participants with pulmonary hypertension diagnosed in the first 24 hours after birth.

    Pulmonary hypertension is present if at least 2 of the following 4 criteria are present or if the infant requires extracorporeal membrane oxygenation (ECMO) in the first 24 hours after birth: 1. Right ventricular systolic pressure (RVSP) ≥2/3 systemic systolic pressure\* 2. Right ventricle (RV) dilatation/septal displacement or RV dysfunction +/- left ventricle (LV) dysfunction\* 3. Pre-post ductal SpO2 difference \>10% for at least 15 consecutive minutes 4. Oxygenation Index \>20\*\* \*as found on first ultrasound in first 24 hours after birth; \*\*highest value measured in first 24 hours after birth The following echocardiographic parameters will be collected to objectify these criteria: * RV size * Pulmonary artery acceleration time (PAAT), right ventricular ejection time (RVET), PAAT:RVET ratio * Intraventricular septum configuration * LV systolic eccentricity index * Mean airway pressure * PaO2 * FiO2 * Preductal+postductal SpO2

    Time frame: First 24 hours after birth

Secondary outcomes

  1. Neonatal: mortality before discharge from the tertiary care hospital

    Number of patients that died before discharge

    Time frame: From birth till discharge from the tertiary care hospital, through study completion an average of one year

  2. Neonatal: presence of 3 or more criteria for pulmonary hypertension or extracorporeal membrane oxygenation within 24 hours after birth

    Number of patients with 3 or more criteria or ECMO

    Time frame: The first 24 hours after delivery

  3. Neonatal: number of patients requiring ECMO therapy

    Number of patients requiring ECMO therapy

    Time frame: From admission to the ICU until the date of death or the date of discharge home, whichever came first

  4. Neonatal: number of days of duration of supplemental oxygen need

    Number of days of duration of supplemental oxygen need

    Time frame: From admission to the ICU until the date of discharge to another ward or home, whichever came first,through study completion an average of one year

  5. Neonatal: number of days of duration of mechanical ventilation

    Number of days of duration of mechanical ventilation

    Time frame: From admission to the ICU until the date of discharge to another ward or home, whichever came first,through study completion an average of one year

  6. Neonatal: duration of admission to the tertiary care hospital

    Number of days of admission to the tertiary care hospital

    Time frame: From admission to the ICU until the date of discharge to another ward or home, whichever came first

  7. Maternal: number of patients with postpartum haemorrhage

    Postpartum haemorrhage is defined as estimated blood loss \>1000 mL

    Time frame: The first 24 hours after delivery

07

Study locations

9 sites
  • Monash University
    Melbourne, Australia
  • Medical University Graz
    Graz, Austria
  • University Hospitals leuven
    Leuven, Belgium
  • Universitätskrankenhaus Bonn
    Bonn, Germany
  • Universitätsklinik Mannheim
    Mannheim, Germany
  • Ospedale Pediatrico Bambino Gesu
    Rome, Italy
  • Radboudumc University Medical Center
    Nijmegen, Netherlands
  • Erasmus MC University Medical Center - Sophia Children's Hospital
    Rotterdam, Netherlands
  • Karolinska University Hospital
    Stockholm, Sweden
08

References and documents

Publications

  • Horn-Oudshoorn EJJ, Vermeulen MJ, Knol R, Bout-Rebel R, Te Pas AB, Hooper SB, Otter SCMC, Wijnen RMH, Crossley KJ, Rafat N, Schaible T, de Boode WP, Debeer A, Urlesberger B, Roberts CT, Kipfmueller F, Capolupo I, Burgos CM, Hansen BE, Reiss IKM, DeKoninck PLJ. Multicentre, randomised controlled trial of physiological-based cord clamping versus immediate cord clamping in infants with a congenital diaphragmatic hernia (PinC): statistical analysis plan. Trials. 2024 Mar 20;25(1):198. doi: 10.1186/s13063-024-08027-7. PubMed 38509614 ↗
  • Horn-Oudshoorn EJJ, Knol R, Vermeulen MJ, Te Pas AB, Hooper SB, Cochius-den Otter SCM, Wijnen RMH, Crossley KJ, Rafat N, Schaible T, de Boode WP, Debeer A, Urlesberger B, Roberts CT, Kipfmueller F, Reiss IKM, DeKoninck PLJ. Physiological-based cord clamping versus immediate cord clamping for infants born with a congenital diaphragmatic hernia (PinC): study protocol for a multicentre, randomised controlled trial. BMJ Open. 2022 Mar 18;12(3):e054808. doi: 10.1136/bmjopen-2021-054808. PubMed 35304395 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Jan 2026, 67 months.

Of 40 interventional studies with no phase under Hernias, Diaphragmatic, Congenital, half reached primary completion within 108 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 133. This study's 67 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Jun 2026 → Jan 2026 and completion Jul 2026 → Jan 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2020
First posted
May 5, 2020
StartActual
May 11, 2020
Primary completionActual
Jan 1, 2026was Jun 2026
CompletionActual
Jan 15, 2026was Jul 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Sep 25, 2026
Primary completion
Jun 1, 2026→Jan 1, 2026 (actual)
Sep 25, 2026
Study completion
Jul 1, 2026→Jan 15, 2026 (actual)
Sep 25, 2026
Enrollment
140 (estimated)→144 (actual)
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Active, not recruiting→Completed
    Primary completion Jun 1, 2026→Jan 1, 2026 (now actual)
    Study completion Jul 1, 2026→Jan 15, 2026 (now actual)
    Enrollment 140 (estimated)→144 (actual)
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04373902
Responsible party
Philip L.J. DeKoninck (Principal Investigator, Dr., Erasmus Medical Center) — Principal investigator
First posted
May 5, 2020
Start date
May 11, 2020
Primary completion
Jan 1, 2026
Completion
Jan 15, 2026
Last update
Sep 25, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion